Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study
Clicks: 195
ID: 273326
2021
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
30.0
/100
195 views
29 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #34 of 45 articles by views in Frontiers in oncology
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
The development of an early exanthema within 6 weeks after treatment start indicates a favorable therapy outcome upon vemurafenib plus cobimetinib. Patients presenting with an early exanthema should therefore be treated with adequate supportive measures to provide that patients can stay on treatment …
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (42 words).
Try re-searching for a better abstract.
| Reference Key |
kc2021frontiersearly
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Kähler KC;Gutzmer R;Meier F;Zimmer L;Heppt M;Gesierich A;Thoms KM;Utikal J;Hassel JC;Loquai C;Pföhler C;Heinzerling L;Kaatz M;Göppner D;Pflugfelder A;Bohne AS;Satzger I;Reinhardt L;Placke JM;Schadendorf D;Ugurel S;; |
| Journal | Frontiers in oncology |
| Year | 2021 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.